Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48 + camrelizumab + S-1 neoadjuvant therapy for HER2-overexpressing locally advanced gastric cancer
ChiCTR2300075446Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin, camrelizumab and tegafur in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Shandong Cancer Hospital. Primary endpoint: Complete pathological response rate. Started Nov 2022; status: recruiting.
02
Drugs
disitamab vedotincamrelizumabtegafur
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300075446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075446.